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A bs tr ac t
Background
In the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified 
Release Controlled Evaluation (ADVANCE) factorial trial, the combination of perin-
dopril and indapamide reduced mortality among patients with type 2 diabetes, but 
intensive glucose control, targeting a glycated hemoglobin level of less than 6.5%, 
did not. We now report results of the 6-year post-trial follow-up.
Methods
We invited surviving participants, who had previously been assigned to perindo-
pril–indapamide or placebo and to intensive or standard glucose control (with the 
glucose-control comparison extending for an additional 6 months), to participate 
in a post-trial follow-up evaluation. The primary end points were death from any 
cause and major macrovascular events.
Results
The baseline characteristics were similar among the 11,140 patients who originally under-
went randomization and the 8494 patients who participated in the post-trial follow-up for 
a median of 5.9 years (blood-pressure–lowering comparison) or 5.4 years (glucose-control 
comparison). Between-group differences in blood pressure and glycated hemoglobin lev-
els during the trial were no longer evident by the first post-trial visit. The reductions in the 
risk of death from any cause and of death from cardiovascular causes that had been ob-
served in the group receiving active blood-pressure–lowering treatment during the trial 
were attenuated but significant at the end of the post-trial follow-up; the hazard ratios 
were 0.91 (95% confidence interval [CI], 0.84 to 0.99; P = 0.03) and 0.88 (95% CI, 0.77 to 
0.99; P = 0.04), respectively. No differences were observed during follow-up in the risk of 
death from any cause or major macrovascular events between the intensive-glucose-
control group and the standard-glucose-control group; the hazard ratios were 
1.00 (95% CI, 0.92 to 1.08) and 1.00 (95% CI, 0.92 to 1.08), respectively.
Conclusions
The benefits with respect to mortality that had been observed among patients 
originally assigned to blood-pressure–lowering therapy were attenuated but still 
evident at the end of follow-up. There was no evidence that intensive glucose control 
during the trial led to long-term benefits with respect to mortality or macrovascular 
events. (Funded by the National Health and Medical Research Council of Australia 
and others; ADVANCE-ON ClinicalTrials.gov number, NCT00949286.)
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Post-trial follow-up studies involv-ing patients with diabetes have previously shown long-term beneficial effects of ear-
lier periods of intensive glucose control, but not 
blood-pressure lowering, on a range of outcomes, 
including mortality and macrovascular events.1-3 
The Epidemiology of Diabetes Interventions and 
Complications (EDIC) study, an extension of the 
Diabetes Control and Complications Trial (DCCT) 
involving young patients with type 1 diabetes and 
no history of cardiovascular disease, hyperten-
sion, or hypercholesterolemia, showed a lower risk 
of macrovascular events, as well as a sustained ben-
efit with respect to microvascular complications, 
beyond the period of intensive glucose control.1 The 
post-intervention follow-up of the United King-
dom Prospective Diabetes Study (UKPDS) also 
showed long-term beneficial effects of intensive 
glucose control in patients with newly diagnosed 
type 2 diabetes.2 Among patients formerly as-
signed to intensive therapy as compared with 
conventional therapy, the reduced risk of micro-
vascular events was maintained, and previously 
nonsignificant estimates of the effect of inten-
sive therapy on the end points of death and myo-
cardial infarction became significant with extend-
ed follow-up.2 In contrast, no long-term benefits 
were detected with improved blood-pressure con-
trol in the UKPDS.3
The Action in Diabetes and Vascular Disease: 
Preterax and Diamicron Modified Release Con-
trolled Evaluation (ADVANCE) trial assessed the 
effects of routine blood-pressure lowering and 
intensive glucose control in a broad cross section 
of patients with type 2 diabetes.4,5 Routine ad-
ministration of a single-pill (fixed-dose) combina-
tion of perindopril and indapamide was associ-
ated with a reduction in the risk of the primary 
composite end point of major macrovascular or 
microvascular events. Reductions in the risks of 
death from any cause, death from cardiovascular 
causes, and nephropathy were also observed.4 
Intensive glucose control was associated with a 
reduction in the risk of the primary composite 
end point of major macrovascular or microvas-
cular events, owing primarily to a reduction in 
the incidence of new or worsening nephropathy.5 
This benefit with respect to nephropathy included 
a reduction in the incidence of end-stage renal 
disease but not of death from renal disease.6 No 
clear protective or harmful effects of intensive 
glucose control with respect to death from any 
cause or major macrovascular events were iden-
tified.5 We now report the results from the post-
trial follow-up of the ADVANCE-Observational 
Study (ADVANCE-ON), which was designed to test 
the hypotheses that there would be long-term 
benefits of the two active interventions.
Me thods
Randomized Trial
Details of the recruitment of patients and the 
study design and methods have been published 
previously.7 In brief, 11,140 patients, 55 years of 
age or older, with type 2 diabetes and at least one 
additional risk factor for cardiovascular disease 
were enrolled between 2001 and 2003 at 215 cen-
ters in 20 countries. The study had a 2-by-2 facto-
rial design. Patients were randomly assigned to a 
single-pill (fixed-dose) combination of perindo-
pril (4 mg) and indapamide (1.25 mg) or match-
ing placebo, after a 6-week active run-in period, 
and were also randomly assigned to a gliclazide 
(modified release)–based intensive glucose-control 
regimen, targeted to achieve a glycated hemoglo-
bin level of 6.5% or lower, or to standard glucose 
control, with targets and regimens based on lo-
cal guidelines. There were no inclusion or exclu-
sion criteria related to blood pressure, and no 
blood-pressure targets were specified. The use of 
concomitant treatments during the trial, includ-
ing other blood-pressure–lowering and glucose-
control therapy, was at the discretion of the re-
sponsible physician. The last trial visits for the 
randomized blood-pressure–lowering compari-
son were completed in June 2007 after a median 
follow-up period of 4.4 years, at which time pa-
tients resumed their usual care for blood-pressure 
control.4 The randomized glucose-control regi-
men continued for an additional 6 months, to 
ensure adequate study power in the context of a 
smaller-than-anticipated separation in glycated 
hemoglobin levels between the groups. The last 
trial visits for the glucose-control comparison were 
completed in January 2008 after a median follow-
up period of 5.0 years.5 At this time, all the pa-
tients discontinued their randomly assigned in-
tervention and returned to the care of their usual 
physician for all aspects of treatment.
Post-Trial Follow-up
ADVANCE-ON was a post-trial follow-up study in-
volving all surviving patients from the ADVANCE 
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trial. A detailed description of the original study 
protocol has been published previously, and the 
current protocol, including the statistical analy-
sis plan (which was completed before the end of 
the follow-up period), is available with the full 
text of this article at NEJM.org. ADVANCE-ON 
was an investigator-initiated study that was de-
signed, conducted, analyzed, and interpreted in-
dependently of the funders, including the com-
mercial sponsor (Servier International). Servier 
International was given the opportunity to com-
ment on the final draft of the manuscript but had 
no role in the decision to submit the manuscript 
for publication. The first two authors wrote all 
drafts of the manuscript. The writing committee 
(i.e., all the authors) and the management com-
mittee (see the Supplementary Appendix, available 
at NEJM.org), neither of which included represen-
tatives of the sponsors, had final responsibility for 
the manuscript and for the decision to submit it 
for publication.
Two years after completion of the final 
ADVANCE trial visits, all local trial sites were 
invited to participate in the follow-up study, and 
172 of 215 (80%) agreed. After approval of the 
study by the ethics review board at each site, all 
surviving trial patients were invited to partici-
pate in the post-trial follow-up. In January 2010, 
annual post-trial visits commenced. At the first 
post-trial visit, all the participants provided writ-
ten informed consent and completed a standard-
ized questionnaire on the occurrence of all study 
outcomes of interest and all medications they 
were taking. A random subgroup of 2000 pa-
tients, balanced across regions and across the 
prior randomized study groups, were also invit-
ed to undergo assessment of the glycated hemo-
globin level, fasting blood glucose level, blood 
pressure, weight, serum creatinine level, and 
urinary albumin-to-creatinine ratio at the first 
post-trial visit, to determine whether differences 
observed during the trial (in-trial period) per-
sisted. For patients known to have died after the 
final in-trial visit, the cause and date of death 
were recorded. For patients unwilling or unable 
to attend study visits in person, follow-up as-
sessments were conducted by telephone or home 
visit, or information was provided by the primary 
care physician, other health care providers, or 
next of kin. At annual visits, patients completed 
a questionnaire on medication taken and study 
outcome events. In addition, at the final visits, 
which occurred between January 1, 2013, and Feb-
ruary 28, 2014, patients attending visits in per-
son were invited to undergo an assessment of the 
glycated hemoglobin level, fasting blood glucose 
level, weight, blood pressure, serum creatinine 
level, and urinary albumin-to-creatinine ratio, re-
gardless of whether they had undergone these 
assessments at the first visit.
Study Outcomes
The two prespecified primary outcomes for the 
present study were death from any cause and ma-
jor macrovascular events (a composite, as in the 
randomized trial, of nonfatal myocardial infarc-
tion, nonfatal stroke, or death from any cardio-
vascular cause). The prespecified secondary out-
comes were death from cardiovascular causes, 
fatal or nonfatal myocardial infarction, fatal or 
nonfatal stroke, major clinical microvascular events 
(a composite of end-stage renal disease, defined 
as requirement for renal-replacement therapy; 
death from renal disease; requirement for retinal 
photocoagulation; or diabetes-related blindness 
in either eye), the separate components of this 
composite outcome, and major hypoglycemia (as 
defined in the original trial protocol5). It was not 
possible to replicate the outcomes, “major micro-
vascular events” and “new or worsening nephrop-
athy,” as defined in the original trial, because 
levels of serum creatinine and urinary albumin 
were measured in only a subgroup of participants 
during the post-trial follow-up. Outcomes occur-
ring during the post-trial follow-up period were 
as reported by investigators at the study centers, 
according to prespecified definitions and criteria, 
and were not centrally adjudicated.
Statistical Analysis
All analyses were performed according to the ini-
tial study-group assignment. Treatment effects 
were examined with the use of cumulative-inci-
dence survival curves and Cox proportional-haz-
ards models. Data were censored at the time of 
the first relevant end point, the date of the pa-
tient’s death, the date of the patient’s last visit 
(for those still alive), or, for patients whose vital 
status was unknown at the end of the study (Feb-
ruary 28, 2014), the date the patient was last 
known to be alive. Hazard ratios were estimated 
for the in-trial period and over the entire period 
of follow-up according to the intention-to-treat 
principle. We also performed a nonrandomized, 
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observational analysis of incident events during 
the post-trial period alone. Serial hazard ratios 
with 95% confidence intervals were estimated at 
the end of each calendar year of post-trial follow 
up. Each hazard ratio was obtained from a Cox 
model that included all the data collected up to 
the end of that calendar year. The interaction be-
tween the effects of intensive glucose control and 
blood-pressure lowering and the homogeneity of 
treatment effects in prespecified subgroups were 
tested by adding an interaction term to the rele-
vant Cox models. A sensitivity analysis that includ-
ed data only from sites that were able to follow at 
least 85% of surviving patients was performed 
for the entire period of follow-up.
The analyses were performed with the use of 
SAS software, version 9.2. All tests were two-sided, 
and P values of less than 0.05 were considered to 
indicate statistical significance. The protocol 
prespecified that no adjustments would be made 
for the multiple statistical testing.8 In light of 
this, the findings were interpreted with caution.
R esult s
Follow-up
Of the 10,261 participants who were alive when 
the blood-pressure–lowering comparison was com-
pleted and the 10,082 patients who were alive when 
the glucose-control comparison was completed, 
8494 (83% and 84%, respectively) enrolled in the 
post-trial follow up; 5131 of the 7279 patients 
who were alive at the end of the follow-up period 
(70%) completed a visit during the final year of 
the follow-up study (Fig. S1 and S2 in the Supple-
mentary Appendix). The first post-trial visits oc-
curred a median of 3.5 years after the final trial 
visit for the blood-pressure–lowering compari-
son and 2.9 years after the final trial visit for the 
glucose-control comparison. The median in-trial, 
post-trial, and total follow-up periods were 4.4 
years, 5.9 years, and 9.9 years, respectively, for 
the blood-pressure–lowering comparison and 
5.0 years, 5.4 years, and 9.9 years, respectively, 
for the glucose-control comparison.
Characteristics of the Patients
The prerandomization characteristics of the en-
tire trial cohort and of the cohort that contrib-
uted further data during the post-trial follow-up 
are shown according to the original study-group 
assignment; the characteristics were similar in 
the two cohorts apart from such changes as are 
consistent with a healthy-survivor effect in the 
post-trial cohort (Table 1). The prerandomization 
characteristics of the subgroups that had bio-
chemical levels measured at the first and final 
post-trial visits were also similar to those of the 
entire cohort (Table S1 in the Supplementary Ap-
pendix). In addition, the prerandomization char-
acteristics of the patients who completed a visit 
in the final year of post-trial follow-up were sim-
ilar to those of patients who did not (Table S2 in 
the Supplementary Appendix).
Treatment Patterns
After completion of the blood-pressure–lowering 
comparison of the trial, the use of perindopril–
indapamide, other blood-pressure–lowering ther-
apies, and other medications was well balanced 
between the group that had originally been as-
signed to perindopril–indapamide and the group 
that had originally been assigned to placebo (Ta-
ble S3 in the Supplementary Appendix). The use 
of blood-pressure–lowering therapies had de-
creased by the first post-trial visit and then in-
creased by the final post-trial visit, although ap-
proximately 20% of the patients remained off 
any such therapy.
After completion of the glucose-control com-
parison of the trial, the use of oral glucose-lower-
ing therapies and insulin in the group that had 
originally been assigned to intensive glucose 
control and the group that had originally been 
assigned to standard glucose control converged, 
although some differences remained between 
the two groups (Table S4 in the Supplementary 
Appendix). The use of insulin increased more in 
the standard-control group than in the intensive-
control group, whereas the use of sulfonylureas, 
including modified-release gliclazide, decreased 
in both groups over time.
Blood Pressure and Glycemic Control
The mean between-group difference in blood pres-
sure observed during the randomized ADVANCE 
trial (5.6/2.2 mm Hg, P<0.001)4 was no longer 
evident 6 months after the end of that part of the 
trial: the blood pressures recorded at the time of 
the final randomized visit for the patients in the 
glucose-control comparison (6 months after the 
last visit for the blood-pressure control compari-
son) were 137/74 mm Hg in the perindopril–inda-
pamide group and 136/74 mm Hg in the placebo 
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Figure 1 (facing page). Cumulative Incidence of Events, 
According to Blood-Pressure–Lowering Study Group.
Shown is the percentage of patients who had events at 
any time after the start of randomized treatment in the 
Action in Diabetes and Vascular Disease: Preterax and 
Diamicron Modified Release Controlled Evaluation 
(ADVANCE) trial, according to assignment to the ac-
tive-drug (perindopril–indapamide) group or the place-
bo group. Cumulative hazard ratios (active-drug group 
vs. placebo group) and P values are shown for a 12-
year period from the start of randomized treatment to 
the end of the post-trial follow-up in the ADVANCE–
Observational Study (ADVANCE-ON). The insets in 
Panels A and C (which show outcomes that were re-
duced significantly with the active drug) display the 
same data on an enlarged y axis.
group. The levels remained similar in the two 
blood-pressure–lowering study groups through the 
post-trial period (Table S5 in the Supplementary 
Appendix).
The mean between-group difference in gly-
cated hemoglobin levels (0.67 percentage points, 
P<0.001)5 observed during the randomized 
ADVANCE trial was no longer evident by the 
first post-trial visit, an average of 2.9 years later 
(0.08 percentage points; 95% confidence inter-
val [CI], −0.07 to 0.22; P = 0.29), and the levels 
remained similar at the conclusion of the post-
trial follow-up (7.2% in the intensive-therapy 
group and 7.4% in the standard-therapy group) 
(Table S6 in the Supplementary Appendix).
Other Risk Factors
Among the patients included in the blood-pres-
sure–lowering comparison, the incidences of other 
risk factors were well balanced between the per-
indopril–indapamide group and the placebo group 
(Table S5 in the Supplementary Appendix). Among 
the patients included in the glucose-control com-
parison, the small difference of 1.6 mm Hg in 
systolic blood pressure that had been observed, on 
average, between the two glucose-control groups 
during the trial was diminished and no longer 
significant at the first post-trial visit (1.2 mm Hg, 
P = 0.17) and the final post-trial visit (0.9 mm Hg, 
P = 0.14). The mean body weight, serum creati-
nine level, and urinary albumin-to-creatinine ratio 
were similar in the intensive and standard glu-
cose-control groups at the final post-trial visit 
(Table S6 in the Supplementary Appendix).
Primary Outcomes
During the randomized blood-pressure interven-
tion, 879 patients died and 1000 patients had a 
major macrovascular event (Table 2). During the 
post-trial follow-up period, an additional 1386 
patients died and 1166 patients had an incident 
major macrovascular event. Among patients as-
signed to perindopril–indapamide therapy, there 
was a significant but attenuated cumulative bene-
fit with respect to the incidence of death from 
any cause that extended to the end of the overall 
follow-up period (hazard ratio, 0.91; 95% CI, 
0.84 to 0.99; P = 0.03) (Table 2 and Fig. 1A and 
2A) — a finding consistent with the in-trial find-
ing of a significant risk reduction of 14% in the 
rate of death from any cause among patients as-
signed to perindopril–indapamide therapy (haz-
ard ratio, 0.86; 95% CI, 0.75 to 0.98; P = 0.03). 
There was no evidence that the cumulative ef-
fects with respect to death from any cause varied 
according to the subgroups studied, including 
the subgroup defined according to assignment to 
intensive glucose control versus standard glucose 
control (P>0.20 for interaction for all subgroup 
analyses) (Fig. S3 in the Supplementary Appen-
dix). There was no cumulative benefit of perindo-
pril–indapamide with respect to major macrovas-
cular events, and the hazard ratios for this 
composite outcome were similar at the end of the 
in-trial period and at the end of the overall fol-
low-up period, although they were not signifi-
cant at either time (Table 2 and Fig. 1B and 2B).
During the randomized glucose-control inter-
vention, 1031 patients died and 1147 patients 
recorded a major macrovascular event (Table 2). 
During the post-trial period, an additional 1234 
patients died and 1019 patients recorded a major 
macrovascular event. There were no cumulative 
benefits of intensive glucose control with respect 
to either death from any cause or major macro-
vascular events (Table 2 and Fig. 3A and 3B and 
4A and 4B) — results that were consistent with 
in-trial findings. There was no evidence that the 
cumulative effects with respect to death from 
any cause varied according to the patient sub-
groups studied, including the subgroup defined 
according to assignment to active blood-pressure–
lowering therapy versus placebo (P>0.10 for in-
teraction for all subgroup analyses) (Fig. S4 in 
the Supplementary Appendix).
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Figure 2 (facing page). Hazard Ratios for Events,  
According to Blood-Pressure–Lowering Study Group.
Hazard ratios are shown for events that occurred from 
the start of randomized treatment to the end of the 
blood-pressuring–lowering comparison (2007), to the 
end of the glucose-control comparison (2008), and to 
the end of each year of post-trial follow-up (2010 
through 2013). The hazard ratios are for the active-
drug (perindopril–indapamide) group versus the pla-
cebo group. P values are for the between-group com-
parison at the final visit for the randomized trial in 
2007 and at the end of the post-trial follow-up period. 
The data for 2013 include those obtained in the first  
2 months of 2014, when follow-up was terminated.  
T1 indicates the final visit for the blood-pressure-com-
parison cohort, and T2 the final visit for the glucose-
comparison cohort. Vertical lines indicate 95% confi-
dence intervals.
Secondary Outcomes
In the blood-pressure–lowering cohort, an addi-
tional 520 deaths from cardiovascular causes, 
393 myocardial infarctions, and 538 strokes were 
recorded during the post-trial period (Table 2). 
The in-trial reduction in the risk of death from 
cardiovascular causes among those assigned to 
perindopril–indapamide (hazard ratio, 0.82; 95% 
CI, 0.68 to 0.98; P = 0.03) was attenuated but re-
mained significant at the end of the overall fol-
low-up period (hazard ratio, 0.88; 95% CI, 0.77 to 
0.99; P = 0.04) (Table 2 and Fig. 1C and 2C). There 
were no cumulative benefits with respect to any 
other secondary outcome, including major clini-
cal microvascular events (Table 2).
In the glucose-control cohort, an additional 
349 major clinical microvascular events were 
recorded during the post-trial period (Table 2). 
There were no cumulative benefits with respect 
to major clinical microvascular events (Table 2 
and Fig. 3D and 4D) or severe diabetes-related 
eye disease (Table 2 and Fig. 3F and 4F). There 
was a significant cumulative benefit with respect 
to end-stage renal disease (hazard ratio, 0.54; 
95% CI, 0.34 to 0.85; P = 0.007) (Table 2 and Fig. 
3E and 4E), although relatively few events were 
recorded. There was no cumulative benefit with 
respect to death from renal disease or any other 
secondary outcome, including death from car-
diovascular causes, myocardial infarction, and 
stroke (Table 2).
There was no significant interaction between 
the effects of glucose control and blood-pressure 
lowering with respect to any primary or second-
ary outcome (P>0.10 for interaction for all com-
parisons). When the cumulative effects were 
examined with data only from sites that were 
able to follow at least 85% of their surviving 
patients, the findings were unchanged in the 
glucose-control cohort, and the pattern of the ef-
fects in the blood-pressure–lowering cohort re-
mained similar (Table S7 in the Supplementary 
Appendix). However, the reduction in major mac-
rovascular events observed in the perindopril–
indapamide group, which was not significant in 
the total cohort (P = 0.06) (Table 2), did become 
significant when only sites that were able to fol-
low at least 85% of their surviving patients were 
considered (P = 0.03) (Table S7 in the Supplemen-
tary Appendix). Conversely, the reduction in death 
from cardiovascular causes, which was signifi-
cant in the total cohort (P = 0.04), became non-
significant when only sites that were able to 
follow at least 85% of their surviving patients 
were considered (P = 0.06).
When the post-trial observational period was 
examined alone, there was no reduction in the 
risk of any outcome among patients assigned to 
perindopril–indapamide as compared with those 
assigned to placebo or among patients assigned 
to intensive glucose control as compared with 
those assigned to standard glucose control (Ta-
ble S8 in the Supplementary Appendix). Although 
the rate of major hypoglycemia was low overall, 
the increase in that rate in the intensive-glucose-
control group versus the standard-glucose-con-
trol group, which was significant during the 
trial, was not significant at the end of the post-
trial follow-up, when only the post-trial period 
was considered (Table S8 in the Supplementary 
Appendix).
Discussion
After following the current cohort for a total of 
10 years, including the in-trial period and the 
post-trial follow-up, we observed attenuated but 
still significant reductions in the rates of death 
from any cause and from cardiovascular causes 
resulting from the 4.5-year period of blood-pres-
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Figure 3 (facing page). Cumulative Incidence of Events, 
According to Glucose-Control Study Group.
Shown is the percentage of patients who had events 
at any time after the start of randomized treatment, 
according to assignment to the intensive-glucose-con-
trol group or the standard-glucose-control group. 
Hazard ratios (intensive control vs. standard control) 
and P values are shown for the 12-year period from 
the start of randomized treatment to the end of the 
post-trial follow-up. The inset in Panel E (which shows 
an outcome that was reduced significantly with inten-
sive glucose control) displays the same data on an en-
larged y axis.
sure–lowering treatment with perindopril–indap-
amide (average difference in blood pressure of 
5.6/2.2 mm Hg between the perindopril–indap-
amide group and the placebo group during the 
original trial). In contrast, we did not observe any 
significant benefits with respect to mortality, 
macrovascular events, or microvascular events re-
sulting from the 5-year period of intensive glucose 
control (average difference in glycated hemoglo-
bin level of 0.67 percentage points between the 
intensive-glucose-control group and the standard-
glucose-control group during the original trial). 
When the prespecified components of the micro-
vascular outcome were examined, we observed a 
persistent benefit of intensive glucose control with 
respect to end-stage renal disease but no new 
benefit with respect to serious eye complications.
The UKPDS post-trial follow-up study showed 
no persistence of the benefits of the earlier pe-
riod of tight blood-pressure control with respect 
to macrovascular events or death. Although our 
blood-pressure findings appear to be different 
from those of the UKPDS, the point estimates 
for the major mortality end points are similar 
and are consistent with other post-trial follow-up 
studies of blood-pressure–lowering therapy in pa-
tients at high risk for cardiovascular events.9-13 
Indeed, a comparison of in-trial and post-trial 
numbers of events suggests that the cumulative 
reductions in mortality in the perindopril–inda-
pamide group can be ascribed largely to a carry-
ing forward of the effects observed during ran-
domized treatment. It is possible that with even 
longer post-trial follow-up these effects might have 
further dissipated, as occurred in the UKPDS. The 
carry-forward effect and the gradual attenuation 
of benefits over time reinforce the importance of 
continuing blood-pressure–lowering medications 
if the benefits of treatment are to be fully realized.
The DCCT–EDIC and UKPDS post-trial fol-
low-up studies showed the long-term beneficial 
effects of earlier periods of intensive glucose 
control with respect to macrovascular events and 
death.1,2 We did not observe any such long-term 
benefits after post-trial follow-up. In our trial, 
the original benefits of intensive glucose control 
were due primarily to reductions in the incidence 
of new or worsening nephropathy, driven by re-
ductions in the progression of albuminuria and 
serious renal disease requiring renal-replacement 
therapy.5,6 We were unable to obtain the bio-
chemical measurements (serum creatinine level 
and urinary albumin-to-creatinine ratio) required 
to assess the outcome of new or worsening ne-
phropathy in all patients who entered the post-
trial follow-up, so any conclusions can be based 
only on certain components, such as end-stage 
renal disease or death from renal disease. We 
observed benefits with respect to end-stage re-
nal disease but no effects on the rate of death 
from renal disease, which may reflect the persis-
tence of the effects observed during the trial. It 
is possible that the small differences in blood 
pressure between the intensive-glucose-control 
group and the standard-glucose-control group 
during the trial and post-trial periods contrib-
uted up to one quarter of this beneficial effect, 
as was reported for the benefits observed in the 
original trial.5 Given the small number of events 
of end-stage renal disease (29 in the intensive-
control group and 53 in the standard-control 
group), the benefits with respect to this end point 
should be interpreted with caution and studied 
further in future trials.
The divergent outcomes between our study and 
other studies of glucose control in patients with 
diabetes may be explained in part by differences 
in the response to the lowering of glucose across 
the trial populations. First, the younger patients 
with type 1 diabetes (in the DCCT–EDIC)1 or with 
newly diagnosed type 2 diabetes (in the UKPDS)2 
may have been more likely to have long-term 
benefits from glucose lowering than the older 
patients with established disease who were in-
cluded in our study. Second, there were differ-
ences between the studies in the in-trial levels of 
blood glucose, as reflected in the levels of gly-
cated hemoglobin; the glycated hemoglobin level 
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Figure 4 (facing page). Hazard Ratios for Events,  
According to Glucose-Control Study Group.
Hazard ratios are shown for events that occurred from 
the start of randomized treatment to the end of the 
glucose-control comparison (2008) and to the end of 
each year of post-trial follow-up (2010 through 2013). 
The hazard ratios are for the intensive-control group 
versus the standard-control group; values less than 
1.00 represent better outcomes in the intensive-con-
trol group. P values are for the between-group com-
parison at the final visit for the randomized trial in 
2008 and at the end of the post-trial follow-up period. 
The data for 2013 include those obtained in the first  
2 months of 2014, when follow-up was terminated. 
Vertical lines indicate 95% confidence intervals.
differed between study groups by an average of 
0.67 percentage points over a period of 5 years 
in the ADVANCE trial, but the between-group dif-
ference was much larger in the DCCT (2.0 percent-
age points over a mean of 6.5 years during the 
trial) and slightly larger in the UKPDS (0.9 per-
centage points over a median of 10 years during 
the trial).1,2,5 The baseline glycated hemoglobin 
levels in the patients in the DCCT and UKPDS 
(>8.5% in both trials) were also much higher 
than the baseline level in the patients in the 
ADVANCE trial (7.5%).1,2,5 Moreover, during post-
trial follow-up in the UKPDS,2 the mean glycated 
hemoglobin level continued to decrease in both 
groups, whereas in our study, the level remained 
stable in the standard-glucose-control group and 
rose in the intensive-glucose-control group. Third, 
post-trial follow-up of our patients (5 years) was 
shorter than the follow-up for DCCT–EDIC and 
UKPDS (>10 years for both trials) and may have 
been insufficient for benefits to emerge. Fourth, 
it is possible that more widespread use of effective 
background preventive therapy in the ADVANCE 
trial masked the long-term effects. Finally, com-
peting risk, which is a greater issue among older 
patients than among younger patients, may not 
have allowed the full effects of the glucose inter-
vention to be observed in our study.
Our post-trial analysis has some limitations. 
First, our findings must be considered in the con-
text of incomplete follow-up of the total ADVANCE 
cohort. Nevertheless, patients from all the origi-
nal study groups who did participate in the post-
trial follow-up and those who completed a visit 
in the final year of follow up had baseline char-
acteristics that were similar to those in the en-
tire trial population, allowing for the healthy-
survivor effect. Second, end points recorded during 
the post-trial follow-up were not adjudicated; how-
ever, we have previously shown that central adju-
dication in the trial had little effect on the ob-
served hazard ratios for any outcomes.14 Third, 
many follow-up visits were conducted by telephone 
or questionnaire, with complete clinical and bio-
chemical measurements available for only a lim-
ited subgroup of patients; therefore, we were not 
able to assess the possible persistence of bene-
fits with respect to the original microvascular end 
point. Fourth, it should be stressed that although 
a comparison of outcomes across the entire fol-
low-up period preserved the intention-to-treat 
principle, comparisons in the post-trial period 
alone are purely observational and hypothesis-
generating, because they may be confounded by 
differences in risk profiles arising during ran-
domized treatment. Finally, given the multiple 
comparisons made, the results from individual 
hypothesis tests must be considered with caution.
In conclusion, among patients with long-
standing type 2 diabetes, blood-pressure–lower-
ing treatment with perindopril–indapamide for 
an average of 4.5 years resulted in attenuated but 
significant long-term benefits with respect to 
death from any cause and from cardiovascular 
causes, whereas intensive glucose control for an 
average of 5 years did not provide any long-term 
benefits with respect to death or major macro-
vascular events.
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